Compare KEQU & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | BWAY |
|---|---|---|
| Founded | 1906 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 578.5M |
| IPO Year | 1995 | 2011 |
| Metric | KEQU | BWAY |
|---|---|---|
| Price | $34.45 | $13.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 1.6K | ★ 107.3K |
| Earning Date | 03-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ $10.88 | $81.98 |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.27 | $11.77 |
| 52 Week High | $46.70 | $26.63 |
| Indicator | KEQU | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 40.31 |
| Support Level | $33.49 | $11.90 |
| Resistance Level | $35.35 | $14.83 |
| Average True Range (ATR) | 0.95 | 0.47 |
| MACD | -0.30 | -0.04 |
| Stochastic Oscillator | 34.29 | 3.85 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.